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Summary
The unexpected diversity of the human microbiome and metabolome far exceeds the complexity 
of the human genome. Although we now understand microbial taxonomic and genetic repertoires 
in some populations, we are just beginning to assemble the computational and experimental tools 
to understand the metabolome in comparable detail. However, even with the limited current state 
of knowledge, individual connections between microbes and metabolites, between microbes and 
immune function, and between metabolites and immune function are being established. Here we 
provide our perspective on these connections. We also outline a systematic research program that 
could turn these individual links into a broader network that allows us to understand how these 
components interact. This program will allow us to exploit connections among the microbiome, 
metabolome, and host immune system to maintain health, and perhaps help us understand how to 
reverse the processes that lead to a wide range of immune and other diseases.
Introduction
The human microbiota (the collection of microbes that inhabits our bodies) and human 
microbiome (the collection of DNA from microbes) are remarkably, and unexpectedly, 
diverse. Although the Human Microbiome Project (HMP) (Group et al., 2009; Turnbaugh et 
al., 2007) was predicated on the assumption that there would be a large core of microbial 
lineages that we all share, sprinkled with a diversity of “peripheral” lineages that make each 
of us unique (Turnbaugh et al., 2007), this hypothesis was not validated by empirical 
evidence following completion of the HMP. Indeed, the first deep sequencing of multiple 
fecal samples from each of three individuals revealed that the differences between 
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individuals is large. The difference between individuals is substantially greater than the 
difference within an individual at different sampling sites along the distal large intestine 
(Eckburg et al., 2005). This pattern of diversity has subsequently been reinforced in different 
body habitats (Costello et al., 2009; Findley et al., 2013; Grice et al., 2009; Human 
Microbiome Project, 2012), and with larger subject populations, especially in the gut (Qin et 
al., 2010; Turnbaugh et al., 2009; Yatsunenko et al., 2012). Even within healthy Western 
adults, studies routinely show that different people can be >90% different in terms of the 
populations of microbes in their gut: in other words, a microbial cell chosen from person A 
and from person B will be different at the species level more than 90% of the time. 
Additionally, the dynamic range of the most common microbes is hugely variable. Within 
the microbes identified by the European MetaHIT Project as “core”, meaning that they were 
found in at least 90% of the healthy European cohort studied, the dynamic range was several 
orders of magnitude different for each species-- in other words, any microbial species found 
with at least 10% abundance in one person was at least as rare as one cell in 1000 in another 
person in the cohort (Qin et al., 2010). We are at the leading edge of understanding the 
implications of this tremendous diversity at the metabolic level and of the interplay between 
the gut microbiota, metabolic function, and the immune system. To address the molecular 
connections between gut bacteria and immune function, a collection of synergistic 
technologies now exists that will allow rapid progress in untangling these complex 
interactions in ways that may be harnessed to promote health.
Grappling with a diverse microbiota
Although the microbiota is incredibly diverse, and much of this diversity still consists of 
uncharacterized species and genes, defining this diversity for some populations appears 
within reach based on the multitudes of microbiome profiling projects to date. Recent large-
scale studies, such as the HMP and MetaHIT efforts, are beginning to saturate the gene 
catalog for healthy Western cohorts (Human Microbiome Project, 2012; Qin et al., 2010). 
This diversity is usually assessed by a technique called rarefaction: as additional subjects are 
examined, a curve is plotted with the number of subjects on the x-axis, the number of unique 
taxa or genes on the y-axis. As discovery of this microbial “parts list” becomes more 
complete, additional people and subsets of populations are required in order to find a new 
unique part, so the curve levels off, until at last it reaches an asymptote when all the parts 
have been discovered. Similar saturation of rarefaction curves is now being observed for 
several clinical conditions in which the microbiome is involved, such as obesity (Le 
Chatelier et al., 2013) and diabetes (Qin et al., 2012). This finding has several important 
implications: first, that the depth of microbial diversity is addressable using currently 
available technologies; second, that a reference database could be constructed, allowing 
interpretations of new sequences based on matching findings to what is known already 
rather than by computationally-driven de novo assembly and annotation procedures; and 
third, that markers can be discovered within this known universe and then prioritized for 
further laboratory characterization and experimental work, including studies in animal 
models such as those using gnotobiotic mice. However, a cautionary note appears needed: 
studies of children and of non-Western individuals reveal completely different 
configurations of the microbiome and the microbiota (Yatsunenko et al., 2012). 
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Consequently, substantial additional work will be required to extend these techniques to 
cover the diverse complexity found in humanity, a notion that can be extended to various 
conditions in relevant animal models.
Another key assumption made previously that was not validated by subsequent studies is 
that diversity in the microbiota would correlate directly to diversity in the microbiome in 
terms of overall metabolic functions. This property, that different assemblages of species 
converge on very similar functional profiles, was first observed in the human gut 
(Turnbaugh et al., 2009), then more recently extended to other human body sites (Human 
Microbiome Project, 2012). Conceptually, this makes sense in retrospect and by analogy to 
larger-scale ecosystems: two grasslands might look relatively similar to each other, 
especially compared to two forests, even in situations where essentially none of the species 
in either grassland is shared (Hamady and Knight, 2009). Although particular species and 
functions seem to be highly individualized (Fierer et al., 2010; Schloissnig et al., 2013) and 
even stable over time (Caporaso et al., 2011; Faith et al., 2013), and with associations 
between genetic lineages of microbes and functional capacities so highly conserved that 
functional profiles can be predicted accurately from species distributions (Langille et al., 
2013), the overall functional profiles appear remarkably static in healthy subjects overall. 
Although a few studies have correlated the microbiota to the microbiome (Muegge et al., 
2011) and to the metabolome (Ridaura et al., 2013; Smith et al., 2013a), the relationships 
among the various ‘omics’ levels and to the host immune system remain largely unexplored.
Metabolite diversity may exceed even microbial diversity
In contrast to the microbiota and the microbiome, which we are now starting to saturate for 
some populations, the metabolome is extremely diverse and remains largely undescribed and 
undefined. For example, tissue culture cells grown in pure culture remain poorly 
characterized in terms of their metabolic profiles, underscoring the dearth of knowledge 
about more complex biological systems. The human genome contains approximately 20,000 
protein-coding genes, but our metabolomic profile is much more complex, numbering at 
least 500,000 and with individual classes of compounds such as lipids and oligosaccharides 
potentially harboring very high levels of diversity simply on combinatorial grounds 
(Quehenberger et al., 2010; Shevchenko and Simons, 2010). For example, for the molecular 
family of 6 common triacylglycerides that use at least 20 different fatty acids provides the 
combinatorial capacity to make more than 40,000 different lipids (and in reality there are 
many more fatty acids, leading to further combinatorial explosion). This calculation does not 
take in account the many modifications that fatty acids undergo, and the many modifications 
triacylglycerides undergo themselves. This is just one description of one subfamily of one 
molecular family. Furthermore, there are many specialized metabolites including secondary 
metabolites, natural products, quorum sensors and small molecule virulence factors that 
nearly all microbes produce. Some organisms have the metabolic capacity to make as many 
as 50 of these. These molecules are optimized to regulate the surrounding environment and 
to control and alter biology at the host-microbe interface, by driving microbial community 
composition and host immune regulation (Figure 1). In turn, these molecules drive complex 
physiological feedback loops (Nicholson et al., 2005). These microbial molecules have been 
exploited in the clinic as cholesterol-lowering drugs, immune regulators, or antibiotics. 
Dorrestein et al. Page 3
Immunity. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Based on the genome sequences now available, there are strong indications that thousands 
more of these microbial effector molecules remain to be discovered in the human 
microbiota. Finally, given that the diversity of diet-derived cells and microbial cells present 
in the gut dwarf human cell diversity, as well as outnumbering them, it seems appropriate to 
assume that the vast majority of metabolites in our bodies are not of human origin and that 
microbes significantly alter the human microbiome.
The number of potential gut bacterial metabolites is thus currently unknown, and include 
molecules of dietary, host and microbial origin. Furthermore, there is complex crosstalk 
between hosts, microbes, and the transformations that the metabolites undergo. These 
complex transformations often define the ultimate function of the molecules that are present 
(Martin et al., 2007). The tools currently available to harvest and visualize the diversity of 
microbial metabolites, including both primary and specialized metabolites, do not presently 
capture this complexity. Consequently, the state of knowledge for metabolites resembles the 
situation for microbes a decade ago: we know there are myriad metabolites of potential 
microbial origin or of microbial transformation, and we know that some are shared among 
people and some are unique. In a handful of examples that are clinically interesting, 
metabolites and their association with clinical phenotypes have been described using 
targeted techniques (Martin et al., 2007). For example, people are similar in some of the 
common metabolites they contain (such as amino acids or short-chain fatty acids in the gut), 
and that some of this variation correlates with disease. However, we lack a clear 
understanding of how many (and which) microbial metabolites influence host biology, and 
the overall nature of variation in the general population. This is due to the current limitations 
in technical approaches capable of building a comprehensive metabolomic “parts list” on a 
population-level scale. If we perform the analysis at the level of pathways rather than 
individual metabolites, they may appear to be more similar among individuals, but this 
apparent similarity may arise from limitations in the bioinformatics tools used. Just as we 
are starting to appreciate that our microbiomes augment our genome’s capabilities, and 
indeed can be more predictive for classifying people as healthy versus diseased than our 
human genome (Knights et al., 2011; Le Chatelier et al., 2013), we need to expand the 
concept of our metabolome to include the microbially-produced and microbially-modulated 
metabolites as factors contributing to pathogenesis.
Integrating immunology with metabolomics studies: a new frontier
Immunological responses by the host are also diverse, although our view of this diversity 
has been limited by the application of targeted approaches. Traditional research in 
immunology has focused on diverse immune responses to pathogenic infection. Viewed 
through this perspective, conventional wisdom in the field has guided studies to determine 
how the immune system attempts to control infectious agents, how pathogens subvert the 
arsenal of innate and adaptive immune mechanisms, and how individual mutations in the 
host may affect these processes. We now appreciate that host-microbial interactions at 
various body surfaces cannot be fully captured in this simple framework, but will likely need 
to involve complex and dynamic processes. These processes include not only immunity to 
pathogens, but also immune ignorance and/or tolerance mechanisms for symbiotic bacteria 
and opportunistic pathogens that are routinely found in microbiome studies. The functions of 
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the immune system may even include promoting the growth of beneficial microbes, as well 
as limiting the growth of harmful microbes, as the same microbe may be harmful or 
beneficial in the context of different body sites, host physiological status, and so forth. 
Conceivably, individual members of the gut microbiota can have diverse effects on the 
immune system, with some indigenous organisms promoting pro-inflammatory responses 
while others promote anti-inflammatory reactions. A handful of microbes have been 
experimentally shown to directly impact infection (by other species, including bacteria, 
eukaryotes and viruses), autoimmunity and inflammation in animal models. These examples 
together with the genomic information indicate the existence of a vast constellation of 
microbes with bioactive properties waiting to be discovered. Consequently, the interplay 
between the gut microbiota and the immune response is likely far more diverse and dynamic 
than we currently appreciate, and the role that metabolites play in the evolutionary 
connection between symbiotic microbes and their hosts is a frontier of research in the field.
To date, observations connecting the microbiome, the metabolome, and immunological 
responses have been sporadic and incomplete. Investigators have made observations, like 
flashbulbs going off in the dark, but a systematic approach has not yet been applied in any 
complex biological system. Therefore, although we know that connections exist (as detailed 
below), only a small fraction of these connections are known at present. In part, this lack of 
a unified approach is due to “language barriers” among the practitioners of the different 
disciplines, and the lack of a unified research community making a concerted effort to bring 
their collective expertise to bear on these problems. Better ways of representing and 
visualizing the data, especially methods that translate across the various highly multivariate 
datasets collected by each discipline, and research practices and communities that allow 
translation of results among disciplines, will be critical going forward to uncover the diverse 
molecular interplay between gut microbial metabolites and the immune system. This 
perspective describes the current state of the art in our understanding of microbial-
metabolite-immune connections, and provides a framework for the vast and exciting 
potential of developing an integrated program to decode the molecular conversation between 
mammals and their microbiomes. In doing so, we describe a roadmap for explaining current 
observations and discovering new interactions based on microbial metabolites in ways that 
will be useful for basic research, predictive modeling, patient stratification and potentially 
the development of transformative treatments for various diseases.
Microbial metabolism and inflammation
The microbiome produces a wide range of metabolites and has a pervasive effect on various 
host processes, although many of these effects are just starting to be explored in detail. It has 
long been known that bacteria in the gut are involved in metabolizing otherwise indigestible 
food components such as dietary fiber, but additional functions are being discovered at a 
rapid pace. For example, microbial production of vitamins and amino acids is important 
during human infant development (Yatsunenko et al., 2012), and has been implicated in 
malnutrition (Smith et al., 2013a), which in turn affects susceptibility to a variety of 
infectious diseases. Similarly, different bacteria in different people have variable effects on 
the metabolism of drugs ranging from the painkiller acetaminophen (Clayton et al., 2009) to 
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the cardiac glycoside digoxin (Haiser et al., 2013) to the cancer drug cyclophosphamide 
(Viaud et al., 2013), and likely also have an effect on immunomodulatory drugs.
Microbial metabolites have long been implicated in metabolic functions both inside and 
outside the gut (Figure 2). Of these, short chain fatty acid (SCFAs), breakdown products of 
dietary fiber such as butyrate, are especially important as an energy source for intestinal 
epithelial cells. Recent studies have expanded the role of SCFAs from gut bacteria to reveal 
impacts on the immune system (for more detail, see the accompanying Thorburn et al. 
review). Briefly, in ulcerative colitis, an inflammatory bowel disease (IBD), SCFAs are 
reduced, and treatment with dietary fiber provides clinical benefits. Mice raised germ-free 
without any gut bacteria have lower SCFA levels than animals with a complex microbiota 
(Maslowski et al., 2009). This phenotype is attributed to increased intestinal inflammation in 
a mouse model of IBD, suggesting that SCFAs provide beneficial or immunosuppressive 
functions. Accordingly, deletion of GPR43, a sensor of SCFAs, leads to exacerbated 
intestinal disease in mice.
SCFAs directly affect development and function of anti-inflammatory regulatory T cells 
(Tregs), which restrain uncontrolled inflammation. SCFAs, and in particular propionate, 
increase both the proportion and the absolute count of Tregs in germ-free mice, and augment 
Treg function to promote suppression in colitis models (Smith et al., 2013b). Bacteria such 
as spore-forming Group XIVa Clostridia appear to produce butyrate that also promotes Treg 
differentiation both in vivo and in vitro (Furusawa et al., 2013). The effects of SCFAs extend 
beyond TREGS and the gut. For example, mice fed a high-fiber diet had both increased 
SCFA levels and protection from allergic inflammation in the lungs, attributed to effects on 
hematopoiesis of innate immune cells by propionate (Trompette et al., 2014). Collectively, 
these studies highlight how gut microbial metabolites, specifically, SCFAs, provide benefits 
to the host via enhancing the innate and adaptive immune systems in various animal models 
and contexts. Future work will be needed to determine whether this mechanism translates to 
humans. Dietary and microbial interventions for allergic, inflammatory and autoimmune 
diseases would be relatively safe and feasible approaches that could be rapidly validated in 
many populations and societies around the world.
Specific immune signals from microbially-produced metabolites
Many of the diseases that have been linked to the microbiome also have an immunological 
component. These conditions include IBD (Frank et al., 2011; Frank et al., 2007; Gevers et 
al., 2014), obesity (Cotillard et al., 2013; Le Chatelier et al., 2013; Ley et al., 2006; Ridaura 
et al., 2013; Turnbaugh et al., 2009), rheumatoid arthritis (Scher et al., 2013), food allergies 
(Ling et al., 2014), asthma (Fuchs and von Mutius, 2013), and animal models of multiple 
sclerosis (Berer et al., 2011; Lee et al., 2011), autism (Hsiao et al., 2013), resistance to 
infection (Abt et al., 2012; Ichinohe et al., 2011; Khosravi et al., 2014), and a wide range of 
other conditions. Examples of specific microbial triggers including lipopolysaccharide 
(LPS), double stranded RNA (dsRNA), quorum sensing molecules (homoserine lactones and 
their derivatives) are also well-known. We will summarize some of this literature, but these 
topics have been extensively reviewed elsewhere. Microbe-brain connections are also 
increasingly emerging as interesting and important (Cryan and Dinan, 2012). For example, 
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neurotransmitters such as dopamine and serotonin are either produced by bacteria or 
production is stimulated in host cells by the presence of bacteria; viewing these 
neurotransmitters as metabolites that affect the immune system is an important emerging 
perspective (Baganz and Blakely, 2013).
Metabolites and pattern recognition by the immune system
Of particular interest is how molecules produced by bacteria, including metabolites, can act 
in pattern recognition by the immune system. The innate immune system has evolved 
pattern recognition receptors (PRRs) that recognize conserved microbial ligands. Binding to 
these ligands alerts the host to the presence of the microbes that produce them. This class of 
molecules, commonly termed pathogen-associated microbial patterns (PAMPs), has 
primarily been studied in the context of pathogenesis. Remarkably, some PAMPs produced 
by the gut microbiota can also positively impact the immune system and health. For 
example, in a model of intestinal injury and inflammation, more severe disease occurred in 
the absence of commensal microbes, but this effect could be ameliorated by adding LPS or 
lipotiechioc acid (LTA), two highly conserved products produced by microbes (Rakoff-
Nahoum et al., 2004). The beneficial effects of microbial molecules extend beyond the gut. 
For example, peptidoglycan (a PAMP) from gut bacteria augments the function of innate 
immune cells that originate from the bone marrow, such as neutrophils, to help fight off 
systemic bacterial infection (Clarke et al., 2010). Depletion of gut bacteria also renders mice 
susceptible to influenza virus infection in the lungs, and to systemic LCMV infection (Abt et 
al., 2012; Ichinohe et al., 2011). The administration of PAMPs restored the host’s ability to 
control infection, demonstrating that microbial molecules previously studied in the context 
of infection can actually host-protective functions when produced at physiological amounts 
by gut bacteria. Finally, germ-free animals are defective in the differentiation of specific 
innate immune cell subsets that are critical for resistance to systemic bacterial infection 
(Khosravi et al., 2014). Oral administration of microbial ligands restored these defects, 
illustrating that microbial molecules regulate immune system development at its core -- 
during hematopoiesis.
Another example of a PAMP that can act as a beneficial signal, not just as a pathogenic 
trigger, is polysaccharide A (PSA) from the human commensal Bacteroides fragilis 
(Mazmanian et al., 2005). PSA signals to the immune system through a specific PRR to 
induce development and function of Foxp3+ Tregs, which prevent inflammation in the gut 
and in the central nervous system through the effects of interleukin-10 (IL-10) (Ochoa-
Reparaz et al., 2010; Round and Mazmanian, 2010). Therefore, not all interactions between 
microbial molecules and PRRs lead to inflammation and disease (Chu and Mazmanian, 
2013). One can therefore view PRRs as sensors not of pathogens, but of microbes in general. 
Thus, PRRs can be viewed as the immune system’s “eyes” that observe the microbial world, 
with the potential for beneficial or harmful outcomes to the host dependent on the context of 
the interaction. This perspective suggests a reconsideration of term PAMP to a more broad 
terminology proposed by many advocating for the use of microbial associated molecular 
patterns, or MAMPs (Mackey and McFall, 2006). The situation is somewhat analogous to 
antibiotics, which are often used in lower concentrations as signaling molecules in natural 
microbial ecosystems (Linares et al., 2006).
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Microbially derived metabolites affect the immune system
The human immune system is significantly impacted by many common microbially-derived 
molecules. LPS is perhaps the best-studied microbially-produced molecule that impacts the 
inflammatory status of humans or mice, with over 85,000 articles on this topic in PubMed at 
the time of this publication. However, other bacterial molecules are also important. 
Tryptophan, which is an essential amino acid in humans and which we obtain both from our 
diet and from tryptophan biosynthesis by our microbial symbionts, as well as its 
microbially-produced breakdown products, plays an important role in the immune system. 
For example, in mice fed unrestricted tryptophan diets, lactobacilli (typically thought of as 
anti-inflammatory, although the genus Lactobacillus contains considerable genetic and 
phenotypic diversity) produce indole-3-aldehyde, which upregulates IL-22 in the host and 
induces a mucosal response limiting colonization of the gut by the fungal pathogen Candida 
albicans (Zelante et al., 2013). Another interesting case is the common quorum-sensing 
molecule N-(3-oxo-dodecanoyl) homoserine lactone, which disrupts NF-κB signaling 
(Kravchenko et al., 2008). Although no homoserine lactones have yet been detected in the 
gut, the gut microbiome harbors many genes capable of producing this class of signaling 
molecules (Swearingen et al., 2013). Part of the challenge in detecting homoserine lactones 
is that they are rapidly degraded by microbes (Moroboshi et al., 2005; Tinh et al., 2007), and 
they are only produced under specific conditions even by bacteria that contain the relevant 
genes (Wang et al., 2006). Better methods for detecting transiently produced and rapidly 
degraded molecules may be required in order to pinpoint the role of such molecules in 
shaping the gut immune system.
Microbes also contribute to the alteration of arachidonic acid-derived lipids. Although 
mostly studied in the context of pathogenesis (Eberhard et al., 2002), many organisms that 
can metabolize these lipids are found in the normal human microbiota, and alter the amount 
of arachidonic acid and its downstream metabolites such as prostaglandins and leukotrienes. 
For example, colonizing germ-free mice with Bacteroides thetaiotaomicron (B. theta) or 
colonizing them with B. theta and Bifidobacterium longum together increased prostaglandin 
E2 production (Rath et al., 2012). If insufficient arachidonic acid is present in the diet, it can 
also be obtained from hydrolysis of membrane lipids, which store arachidonic acid. 
Arachidonic acid release can be mediated by several mechanisms. Although arachidonic 
acid release has not yet been correlated with or attributed to the gut microbiota, many 
microbes, including many members of the normal gut microbiota, have the necessary 
hydrolases to produce arachidonic acid, and likely perform similar roles as phospholipase 
A2.
Unknown functions of specialized gene clusters in the microbiome: new 
natural products?
Finally, many specialized metabolite-producing gene clusters (for example natural products 
including polyketides, sterols, isoprenoids and non-ribosomally synthesized peptides) are 
found within the gut microbiome. The functions of these metabolites are almost completely 
all unknown. Given that many specialized metabolites isolated from other microbes, such as 
rapamycin, are now in clinical use to control immune-mediated diseases, it is likely that the 
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microbiome has co-evolved numerous gene clusters whose products interact with the 
immune system directly or indirectly, perhaps in concert with other microbial inhabitants of 
the gut. Many microbes produce the classes of molecules we have described, although 
understanding the full phylogenetic spectrum of microbes capable of their production, and 
the conditions under which they are produced, remain largely uncharacterized especially in 
the context of the community.
Defining a research program to integrate microbiota, metabolism and 
immunity
As noted above, many connections have been made between microbes and metabolism, 
between microbes and immunity, and between metabolites and immunity. However, 
connections that link all three are scarce at present. An integrated, comprehensive, discovery 
and hypothesis-driven research program could yield immense dividends in terms of insights 
into all three fields (microbes, metabolism, immunity) and their fascinating connections. We 
therefore define approaches that can systematically identify these connections. In particular, 
these approaches will identify small-molecule phenocopies of what are currently thought to 
be host immune issues: these issues may or may not include known bacterial components. 
We should aim to design a pipeline that transcends descriptive cataloging studies 
(microbiomes, metabolomes, etc), and instead gets to underlying mechanisms that represent 
the molecular foundations host-microbial symbiosis.
A paradigm for studies linking metabolites, microbes, and the immune 
system
An example of what this research program might look like is provided by a recent study 
examining the links between the immune system, the microbiota, and metabolism in a 
mouse model of autism (Hsiao et al., 2013). Briefly, mice born to mothers subject to 
maternal immune activation, which simulates viral infection, develop symptoms that 
resemble autism spectrum disorders (ASD), including lack of social interaction, repetitive 
behavior, deficits in communication, gut barrier dysfunction, immunological changes and 
dysbiosis of the microbiome. This combination of symptoms has been reported in ASD.
Importantly, systematic changes in the serum metabolome are observed, including 
overproduction of a metabolite, 4-ethyl phenyl sulfate (4-EPS), that when individually 
administered to normal mice recapitulates some of the same phenotypes. Introduction of a 
probiotic strain of B. fragilis results in lowered 4-EPS production and also ameliorates 
intestinal and behavioral abnormalities. This combination of immunological manipulation, 
generation of lead microbes and metabolites through untargeted microbiome and metabolite 
profiling, and tests in gnotobiotic mice (initially germ-free mice colonized with defined 
communities of microbes) provides a paradigm for identifying connections -- although we 
emphasize that studies like this that have been performed to date only scratch the surface of 
the full range of microbial and metabolic components of the altered response.
Dorrestein et al. Page 9
Immunity. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Towards an integrative pipeline
A pipeline for identifying novel connections in higher throughput might include a program 
to screen small-molecule compound libraries for effects on immune cells in tissue culture, 
identifying metabolites produced by bacteria or by bacterial communities that have been 
linked to diseases and testing candidate microbes and metabolites, alone or in combination, 
in gnotobiotic mice. Additionally, screening bacteria in high-throughput in organoid systems 
with reporter gene assays to identify immunomodulatory effects may be more facile than use 
of live animals. Essentially, the pipeline needs to include case-control studies to establish 
that there are microbial or metabolic differences to explain in the first place, spatial mapping 
and multivalent characterization (microbiome, metabolome, immune repertoire) to generate 
hypotheses about possible connections, prospective longitudinal studies in humans and 
preclinical experimental manipulation studies in mice or other model systems to establish 
causality. This approach may ultimately lead to drug candidates for clinical trials in humans.
This pipeline will be complicated by the bi-directional connections between the microbiome 
and the immune system. For example, genetic deletion of TLR5, a component of the innate 
immune system that recognizes bacterial flagellin, results in a substantially altered bacterial 
community, which in turn (depending on the microbial background) can lead to phenotypes 
ranging from metabolic syndrome (Vijay-Kumar et al., 2010) to colitis (Carvalho et al., 
2012a; Carvalho et al., 2012b), the latter stemming from an inability to regulate pro-
inflammatory proteobacteria. Additional research has shown that, rather than producing a 
single altered microbiome, TLR5-deficient mice produce different microbiota coupled to 
different phenotypes that can be transmitted vertically within a family (facilitated by the fact 
that mice are coprophagous) (Ubeda et al., 2012). Microbiome profiling and specific 
cytokine assays have been performed in these animals, and some of the phenotypes have 
been transferred to previously germ-free mice by transmitting the altered microbiota. Such 
phenotypes include, fascinatingly, the behavioral phenotype that causes the TLR5-deficient 
mice to overeat and thereby develop metabolic syndrome. Unfortunately, however, the 
combination of microbiome, metabolite and immunological profiling in a longitudinal study 
design that would be ideal for identifying lead microbes and metabolites has not yet been 
performed.
Moving beyond the gut
In our discussions thus far, we have mainly focused on the gut and on systemic effects of gut 
microbes at distal sites, because these have been best studied to date. However, there is 
intriguing although preliminary evidence that there may be microbes at sites previously 
thought to be sterile in healthy adults, including the lungs, the adipose tissue, the pancreas, 
the liver, the amniotic fluid, and even the brain. Studying whether microbes inhabit these 
sites in gnotobiotic mice, and the immunological and host responses at distal sites, together 
with the metabolites produced by the host, the bacteria, or the combination of the two, has 
substantial potential for uncovering fundamentally new mechanisms of disease. Microbial 
metabolites are dramatically understudied in the context of the human nervous system, 
immune system, and metabolism. We propose that future studies should focus on 
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interactions between microbial metabolites and the host in various contexts, conditions and 
diseases.
Finally, most studies to date have treated a given body compartment, such as the skin or the 
gut, as a homogeneous assemblage of microbes-- yet the spatial and dynamic associations of 
particular microbes, their metabolites, and components of the immune response are also 
critical for understanding function at these sites. For example, knowing which bacteria 
colonize which crypts in the gut (Lee et al., 2013; Pedron et al., 2012), and how they 
stimulate stem cell proliferation and other factors linked to IBD or cancer, may provide 
important information not accessible in readouts of the microbiome and/or metabolome 
through stool samples. In the context of IBD, for example, biomarkers in treatment-naive 
patients can be more clearly assessed in mucosal biopsies than in the stool (Gevers et al., 
2014), the latter being frequently used for microbiome assessments due to its accessibility 
via non-invasive sampling. Especially given the success of imaging mass spectrometry in 
understanding how bacteria interact with one another to produce metabolites that they would 
not produce in isolation in pure culture (Traxler et al., 2013; Yang et al., 2009), as well as 
interkingdom interactions between bacteria and fungi (Moree et al., 2012), the potential for 
extending these spatially defined studies into the human body is immense. Furthermore, 
understanding how microbes and metabolites change over time in various contexts may lead 
to predictive models for disease diagnosis and patient stratification. The pipeline we propose 
should reveal how microbes are located spatially: correlating specific metabolite features 
with the microbiome distribution, then testing whether the molecules that co-localize impact 
the immune system, will provide an especially powerful mechanism for generating lead 
compounds for the downstream studies that may extend into the clinic. Unfortunately, this 
sampling is destructive using current methods; discovery of nondestructive readouts of the 
microbiome and metabolome would permit longitudinal within-subjects study designs, 
which, given high variability among individuals, might be important for clinical translation 
of these discoveries to improve human health.
Conclusion
A number of specific interactions between microbes, metabolites and the immune system 
have now been discovered: although many of these examples were identified in the context 
of specific diseases, the broader network of these connections are likely critical for a wide 
range of normal biological processes in the host. Development of a pipeline that allows far 
larger-scale discovery of these connections in both health and disease, in humans and animal 
models, is likely within our reach using technologies that exist today or are in current 
development. In particular, in the same way that microbe and gene catalogs are now 
saturating in many populations, saturating the metabolite repertoire and building reference 
databases that allow matching to known standards will accelerate metabolomic discoveries 
considerably. Similarly, ‘multi-omics’ approaches in which the microbiome, the 
metabolome, and the immune repertoire are assessed simultaneously in the same biological 
specimens will provide considerable advances over current approaches. The prospect of a 
fundamental advance in our understanding of biology, not just of the parts list but of the 
interactions among these parts that lead to a healthy supraorganism, and an engineering-
level basis for developing technologies to arrest or reverse processes that lead to disease, is 
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exciting and feasible. Overcoming the barriers in communication and philosophies among 
diverse disciplines, and among different experimental and computational technologies, may 
catalyze a revolution in understanding the microbe-metabolite-immune connection in 
numerous ways that will benefit mankind.
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Recent research has developed specific connections between particular microbes, 
metabolites, and host immune processes, but a generalized map of this interaction 
network is still lacking. Dorrestein et al. describe these connections, and outline how we 
could move towards a global view.
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Figure 1. The microbe-host interface
Individual differences, including sex-specific differences between men and women (blue 
and red respectively), may control the microbiota or interact with the microbiota to influence 
immune function in several ways, including release of metabolites and direct microbial 
interactions. Much of this interface occurs in the gut (shown inset in the female figure), 
where the intestinal wall provides an interface between metabolites and immunological 
processes in the gut and the influence of these metabolites and immunological processes on 
the host systemically. In addition to normal metabolic function, specialized microbially-
produced metabolic products (second inset), such as signaling molecules and antibiotics may 
play a key and specific role in driving microbial community composition, and subsequently 
the microbiome.
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Figure 2. A simplified depiction of the effects of specific gut microbial or microbial-mammalian 
co-metabolites on different organ systems, including the immune system
SCFA and PSA affect Treg cell development. PGN affects bone resorption. TMAO affects 
the vascular system and influences the risk of heart disease. 4EPS affects brain function and 
leads to anxiety-like behavioral defects similar to those observed in autism. Although some 
of these examples illustrate harmful effects, it is likely that many microbially produced 
metabolites in addition to SCFA and PSA produce beneficial effects on the host, although 
these tend to be less well studied. SCFA: short chain fatty acids; PSA: Polysaccharide A; 
PGN: peptidoglycan; TMA: Trimethylamine; TMAO: Trimethylamine N-oxide; 4EP: 4-
ethylphenol; 4EPS: 4EP: 4-ethylphenol sulfate.
Dorrestein et al. Page 19
Immunity. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
